Defining CD95 as a tumor suppressor gene

被引:119
作者
Müschen, M
Warskulat, U
Beckmann, MW
机构
[1] Univ Cologne, Dept Immunol, Inst Genet, D-50931 Cologne, Germany
[2] Univ Cologne, Med Klin 1, D-50931 Cologne, Germany
[3] Univ Dusseldorf, Dept Internal Med, D-40225 Dusseldorf, Germany
[4] Univ Dusseldorf, Dept Gynecol & Obstet, D-40225 Dusseldorf, Germany
来源
JOURNAL OF MOLECULAR MEDICINE-JMM | 2000年 / 78卷 / 06期
关键词
somatic mutations; apoptosis; antitumor immunity; differentiation; tolerance; invasion;
D O I
10.1007/s001090000112
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The CD95 (Apo-1/Fas) receptor-ligand system is one of the key regulators of apoptosis and is particularly important for the maintenance of lymphocyte homeostasis. There is now broad evidence that susceptibility of tumor cells towards CD95-mediated apoptosis is largely reduced. In the human, germline and somatic mutations of the CD95 gene are associated with a high risk of both lymphoid and solid tumors. Based on these observations a new concept defining CD95 as a tumor suppressor gene is discussed. In addition to CD95, its natural ligand (CD95L) is also implicated in malignant progression. Compared to their nonmalignant counterparts, malignant cells frequently exhibit aberrant de novo expression of CD95L and are able to induce CD95L-mediated apoptosis in bystander cells. The role for neoplastic CD95L expression in local tissue destruction, invasion, and metastatic spread has been established for many tumor types. CD95L expression by malignant cells may counteract the host's antitumor immunity and favors immune escape of the tumor. On this basis, the significance of loss of CD95 and gain of CD95L expression for tumor progression is discussed.
引用
收藏
页码:312 / 325
页数:14
相关论文
共 128 条
[1]   Death pathway genes Fas (Apo-1/CD95) and Bik (Nbk) show no mutations in colorectal carcinomas [J].
Abdel-Rahman, WM ;
Arends, MJ ;
Wyllie, AH ;
Morris, RG ;
Ramadan, ME .
CELL DEATH AND DIFFERENTIATION, 1999, 6 (05) :387-388
[2]   TARGETED MUTATION IN THE FAS GENE CAUSES HYPERPLASIA IN PERIPHERAL LYMPHOID ORGANS AND LIVER [J].
ADACHI, M ;
SUEMATSU, S ;
KONDO, T ;
OGASAWARA, J ;
TANAKA, T ;
YOSHIDA, N ;
NAGATA, S .
NATURE GENETICS, 1995, 11 (03) :294-300
[3]   Inhibition of the alloantibody response by CD95 ligand [J].
Arai, H ;
Chan, SY ;
Bishop, DK ;
Nabel, GJ .
NATURE MEDICINE, 1997, 3 (08) :843-848
[4]   Gene transfer of Fas ligand induces tumor regression in vivo [J].
Arai, H ;
Gordon, D ;
Nabel, EG ;
Nabel, GJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (25) :13862-13867
[5]   Identification of new Fas mutations in a patient with autoimmune lymphoproliferative syndrome (ALPS) and eosinophilia [J].
Aspinall, AI ;
Pinto, A ;
Auer, IA ;
Bridges, P ;
Luider, J ;
Dimnik, L ;
Patel, KD ;
Jorgenson, K ;
Woodman, RC .
BLOOD CELLS MOLECULES AND DISEASES, 1999, 25 (15) :227-238
[6]   Multistep carcinogenesis of breast cancer and tumour heterogeneity [J].
Beckmann, MW ;
Niederacher, D ;
Schnurch, HG ;
Gusterson, BA ;
Bender, HG .
JOURNAL OF MOLECULAR MEDICINE-JMM, 1997, 75 (06) :429-439
[7]   A ROLE FOR CD95 LIGAND IN PREVENTING GRAFT-REJECTION [J].
BELLGRAU, D ;
GOLD, D ;
SELAWRY, H ;
MOORE, J ;
FRANZUSOFF, A ;
DUKE, RC .
NATURE, 1995, 377 (6550) :630-632
[8]   Mutation analysis of CD95 (APO-1/Fas) in childhood B-lineage acute lymphoblastic leukaemia [J].
Beltinger, C ;
Böhler, T ;
Karawajew, L ;
Ludwig, WD ;
Schrappe, M ;
Debatin, KM .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (03) :722-728
[9]  
Beltinger C, 1998, BLOOD, V91, P3943
[10]   Cell surface trafficking of Fas: A rapid mechanism of p53-mediated apoptosis [J].
Bennett, M ;
Macdonald, K ;
Chan, SW ;
Luzio, JP ;
Simari, R ;
Weissberg, P .
SCIENCE, 1998, 282 (5387) :290-293